Form 8-K - Current report:
SEC Accession No. 0001193125-25-214001
Filing Date
2025-09-24
Accepted
2025-09-24 07:05:11
Documents
12
Period of Report
2025-09-24
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d159459d8k.htm   iXBRL 8-K 26684
  Complete submission text file 0001193125-25-214001.txt   141587

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20250924.xsd EX-101.SCH 2833
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20250924_lab.xml EX-101.LAB 17992
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20250924_pre.xml EX-101.PRE 11249
14 EXTRACTED XBRL INSTANCE DOCUMENT d159459d8k_htm.xml XML 3643
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 251335151
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)